Endpoint
The proportion of subjects achieving complete abstinence was 47.2% (77/163) for the acamprosate group and 36.0% (59/164) for the placebo group, demonstrating the superiority of the study drug (P = .039; χ2 test). The difference in complete abstinence rates between the 2 groups was 11.3% (95% CI, 0.6%−21.9%; Table 2).